SEC Form 4 · accession 0001209191-18-056702
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shalini Sharp
Officer — CFO & Executive Vice President
Period of report
Oct 31, 2018
Accepted (ET)
Oct 31, 2018 · 6:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 31, 2018 | M | 12,000 | $0.815 | A | 62,128 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.815 | Oct 31, 2018 | M | 12,000 | D | — | Aug 1, 2022 | Common Stock | 12,000 | 6,963 | D |
Explanation of responses
- F1Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- F21/4th of the option vested one year from May 21, 2012 and then 1/48th monthly thereafter.